Hiu Yu Hillary Leung

Dr. Hiu Yu Hillary Leung

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Circulation
Verified
Journal Article
Open access
LNLong Nguyen-Hoang
Long Nguyen-Hoang
LDLinh Thuy Dinh
Linh Thuy Dinh
ATAngela S.T. Tai
Angela S.T. Tai
DNDuy-Anh Nguyen
Duy-Anh Nguyen
Ritsuko PoohRitsuko Pooh
Ritsuko Pooh
OSOsamu Shimokawa
Osamu Shimokawa
BACKGROUND: This trial aimed to assess the efficacy, acceptability, and safety of a first-trimester screen-and-prevent strategy for preterm preeclampsia in Asia. METHODS: Between August 1, 2019, and February 28, 2022, this multicenter stepped wedge cluster randomized trial included maternity/diagnostic units from 10 regions in Asia. The trial started with a period where all recruiting centers provided routine antenatal care without study-related intervention. At regular 6-week intervals, one cluster was randomized to transit from nonintervention phase to intervention phase. In the intervention phase, women underwent first-trimester screening for preterm preeclampsia using a Bayes theorem-based triple-test. High-risk women, with adjusted risk for preterm preeclampsia ≥1 in 100, received low-dose aspirin from <16 weeks until 36 weeks. RESULTS: Overall, 88.04% (42 897 of 48 725) of women agreed to undergo first-trimester screening for preterm preeclampsia. Among those identified as high-risk in the intervention phase, 82.39% (2919 of 3543) received aspirin prophylaxis. There was no significant difference in the incidence of preterm preeclampsia between the intervention and non-intervention phases (adjusted odds ratio [aOR], 1.59 [95% CI, 0.91–2.77]). However, among high-risk women in the intervention phase, aspirin prophylaxis was significantly associated with a 41% reduction in the incidence of preterm preeclampsia (aOR, 0.59 [95% CI, 0.37–0.92]). In addition, it correlated with 54%, 55%, and 64% reduction in the incidence of preeclampsia with delivery at <34 weeks (aOR, 0.46 [95% CI, 0.23–0.93]), spontaneous preterm birth <34 weeks (aOR, 0.45 [95% CI, 0.22–0.92]), and perinatal death (aOR, 0.34 [95% CI, 0.12–0.91]), respectively. There was no significant between-group difference in the incidence of aspirin-related severe adverse events. CONCLUSIONS: The implementation of the screen-and-prevent strategy for preterm preeclampsia is not associated with a significant reduction in the incidence of preterm preeclampsia. However, low-dose aspirin effectively reduces the incidence of preterm preeclampsia by 41% among high-risk women. The screen-and-prevent strategy for preterm preeclampsia is highly accepted by a diverse group of women from various ethnic backgrounds beyond the original population where the strategy was developed. These findings underpin the importance of the widespread implementation of the screen-and-prevent strategy for preterm preeclampsia on a global scale. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03941886.

2 June 2025 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
HLHiu Yu Hillary Leung
Hiu Yu Hillary Leung
IPIoannis Papastefanou
Ioannis Papastefanou
YCY. Chen
Y. Chen
LNL. Nguyen‐Hoang
L. Nguyen‐Hoang
DND.‐A. Nguyen
D.‐A. Nguyen
LPLiona C. Poon
Liona C. Poon
Objectives: To investigate the impact of aspirin administration on the incidence of preterm birth, according to the type of delivery and gestational age at preterm birth, and to examine the hypothesis that aspirin delays preterm delivery. Methods: This was a secondary analysis of a multicenter stepped‐wedge cluster randomized trial of a first‐trimester screen‐and‐prevent strategy for preterm pre‐eclampsia (PE), which included 18 maternity/diagnostic units in 10 regions across Asia between 1 August 2019 and 28 February 2022. Women deemed to be at high risk for preterm PE according to a Bayes' theorem‐based triple test, i.e. those with an adjusted risk for preterm PE of ≥ 1 in 100, received low‐dose aspirin from < 16 weeks until 36 weeks' gestation. Outcome measures were the incidence of early preterm birth (24 + 0 to 31 + 6 weeks' gestation) and late preterm birth (32 + 0 to 36 + 6 weeks). The treatment effect of aspirin on the rate of preterm birth, stratified by gestational age at birth, type of delivery and presence of pregnancy complications, was estimated by computing the relative risks (RR) between the aspirin and non‐aspirin groups with their 95% CIs. A shift model was designed to evaluate the effect of aspirin on preterm birth, based on the hypothesis that aspirin delays a preterm birth to a more advanced gestational age. Results: In the randomized trial, 42 897/48 647 women accepted screening for preterm PE. Following exclusions, 10 294 and 27 965 women were included in the non‐intervention and intervention phases, respectively. Of the 4688 women at high risk for preterm PE, 2909 (62.05%) received aspirin in the trial. Aspirin was associated with a 42% reduction in the risk of early preterm birth (adjusted relative risk (aRR), 0.577 (95% CI, 0.380–0.852)), and there was a significant upward trend in the rate of late preterm birth accordingly (test for trend, P < 0.01). Similar findings were observed for iatrogenic preterm birth and pregnancies with a small‐for‐gestational‐age neonate. Additionally, aspirin was associated with a 60% reduction in the risk of iatrogenic early preterm birth in pregnancies with PE (aRR, 0.398 (95% CI, 0.192–0.788)). However, aspirin did not have a significant effect on iatrogenic late preterm birth in pregnancies with PE. Aspirin significantly delayed early preterm birth, with the effect decreasing by 0.26 (95% credibility interval, –0.40 to –0.05) weeks for each week of advancing gestation. At 24 weeks, aspirin delayed delivery by 3.63 weeks, while at 37 weeks, the delay was only 0.25 weeks. Conclusions: This secondary explanatory analysis found that early administration of aspirin could effectively reduce the risk of early preterm birth in women at high risk for preterm PE. While the reasons for preterm birth are often multifactorial, this study provides greater insight into the relationship between aspirin and different types of preterm birth at different gestational ages. Our findings support the hypothesis that aspirin helps to prevent preterm birth by delaying the timing of delivery, with a greater impact observed for deliveries that would have occurred at an earlier gestational age had aspirin not been administered. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

1 September 2022 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
HLHiu Yu Hillary Leung
Hiu Yu Hillary Leung
BLB. W. Leung
B. W. Leung
María del Mar GilMaría del Mar Gil
María del Mar Gil
VRV. Rolle
V. Rolle
SMS. Moungmaithong
S. Moungmaithong
LPLiona C. Poon
Liona C. Poon

29 September 2024 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
IWI. Y. M. Wah
I. Y. M. Wah
DSD. S. Sahota
D. S. Sahota
NWN. K. L. Wong
N. K. L. Wong
NLN. M. W. Lee
N. M. W. Lee
CLC. J. Liu
C. J. Liu
LPLiona C. Poon
Liona C. Poon
Objective: To compare the diagnostic performance of different manufacturers' immunoassays for the soluble fms‐like tyrosine kinase‐1 (sFlt‐1)‐to‐placental growth factor (PlGF) ratio with that of a point‐of‐care (PoC) test for glycosylated fibronectin (GlyFn) in women with suspected pre‐eclampsia (PE).Methods: This was a prospective, single‐center, double‐blinded, non‐interventional study of East Asian women with a singleton pregnancy who presented with hypertension with or without clinical features of PE after 20 weeks' gestation between January 2020 and March 2022. Maternal serum samples were collected at the time of presentation, and subsequent management followed the departmental protocol, based on gestational age, severity of hypertension, fetal condition and presence of severe PE features. Women diagnosed with PE at presentation were excluded. PE was diagnosed according to the 2018 International Society for the Study of Hypertension in Pregnancy classification. Levels of sFlt‐1 and PlGF were measured using the Cobas e411 (Roche Diagnostics), BRAHMS KRYPTOR (ThermoFisher Scientific) and iMAGIN 1800 (Ningbo Aucheer) platforms. GlyFn levels were measured using the Lumella™ GlyFn PoC test (DiabetOmics Inc.). The predictive performance of each test to rule out PE within 7 days and rule in PE within 28 days from the date of presentation was assessed. Based on the PROGNOSIS study, a sFlt‐1/PlGF ratio of ≤ 38 on the Roche platform was used to predict the absence of PE within 7 days. The sFlt‐1/PlGF ratio was classified as high or low using platform‐specific thresholds equivalent to a Roche sFlt‐1/PlGF ratio of 38, which were derived using Passing–Bablok regression. GlyFn was categorized as high or low using two reported clinical management thresholds (263 μg/mL and 510 μg/mL).Results: Overall, 236 women with suspected PE were included, of whom 70 (29.7%) were diagnosed with PE; 36 (51.4%) and 70 (100%) developed PE within 7 days and 28 days, respectively. Eighty‐eight (37.3%) women had a sFlt‐1/PlGF ratio of > 38 on the Roche platform, 79 (33.5%) women had a sFlt‐1/PlGF ratio of > 55 on the KRYPTOR platform and 96 (40.7%) women had a sFlt‐1/PlGF ratio of > 40 on the iMAGIN 1800 platform. Furthermore, 62 (26.3%) and four (1.7%) women had a GlyFn level of > 263 μg/mL and > 510 μg/mL, respectively. The negative predictive value (NPV) of the sFlt‐1/PlGF ratio measured on the Roche, KRYPTOR and iMAGIN 1800 platforms to rule out PE within 7 days after presentation was 83.3%, 82.0% and 82.9%, respectively, while that for GlyFn > 263 μg/mL and > 510 μg/mL was 82.6% and 70.4%, respectively. The corresponding positive predictive values (PPV) to rule in PE within 28 days after presentation were 50.5%, 52.3% and 46.7%, respectively, for the sFlt‐1/PlGF ratio, and 35.4% and 50.0%, respectively, for GlyFn > 263 μg/mL and > 510 μg/mL.Conclusions: The predictive performance of different manufacturers' assays for the sFlt‐1/PlGF ratio to rule in and rule out PE were similar once standardized to a common threshold. Our findings suggest that the sFlt‐1/PlGF ratio and GlyFn using a cut‐off of 263 μg/mL can both be utilized to rule out PE within 7 days after assessment, with a moderate NPV. The PPV for ruling in PE within 28 days remains poor. © 2024 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

16 July 2024 in Maternal-Fetal Medicine
Verified
Journal Article
Open access
HLHiu Yu Hillary Leung
Hiu Yu Hillary Leung
TMTeresa Wl Ma
Teresa Wl Ma
FYFlorrie Ny Yu
Florrie Ny Yu
MKMeliza Cw Kong
Meliza Cw Kong
TLTsz Kin Lo
Tsz Kin Lo
LPLiona C. Poon
Liona C. Poon
Objective: To report the clinical maternal and fetal outcomes of pregnant women with coronavirus disease 2019 (COVID-19), along with any associated pregnancy complications, in Hong Kong, China, and to assess the impact of COVID-19 vaccination on these outcomes. Methods: This prospective registry-based observational study included pregnant women who were recruited through convenient sampling and had a laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection with a cycle threshold (Ct) value result available on admission to eight local hospitals in Hong Kong, China. Data on clinical symptoms, laboratory results, medical treatments, delivery timing and mode, and pregnancy complications were extracted from the Hospital Authority’s electronic medical record system. Maternal, fetal, and pregnancy outcomes were compared between unvaccinated pregnant women with COVID-19 and those who had received at least one dose of COVID-19 vaccine before diagnosis. Nonparametric continuous variables and categorical variables were analyzed using the Mann-Whitney U test and the Pearson’s chi-squared test respectively. A P value less than 0.05 was considered statistically significant. Results: A total of 164 pregnant women were included, of whom 78 (47.56%) were nulliparous. COVID-19 was diagnosed before 28 weeks’ gestation in 30 (18.29%), while 134 (81.71%) were diagnosed at or after 28 weeks’ gestation. Sixty-two (37.80%) women received at least one dose of COVID-19 vaccine. There were no significant differences between vaccinated and unvaccinated groups in the time interval between COVID-19 diagnosis and delivery, the Ct value, and the gestational age at infection onset or delivery (P > 0.05). The majority of women were symptomatic at diagnosis regardless of vaccination status (55 (88.71%) in vaccinated group vs. 78 (76.47%) in unvaccinated group (P = 0.052). Symptoms did not significantly differ between groups except for cough (62.90% vs. 47.06%, P = 0.049). The overall rate of severe COVID-19 in pregnant women was low. In total, 5 (3.05%) patients experienced severe COVID-19, with vaccinated patients more likely to receive low molecular weight heparin (LMWH) as part of their treatment (62.90% vs. 42.16%, P = 0.010). Ninety-two (56.10%) women had a spontaneous vaginal delivery, 7 (4.27%) had an instrumental delivery, and 44 (26.83%) and 21 (12.80%) underwent emergency and elective cesarean sections respectively. For fetal outcomes, 14 (8.48%) babies were born preterm and four (2.65% of nonpreterm babies, n = 151) had low birthweight. The median birthweight percentile was 52.18th. There were no statistically significant differences in pregnancy complications or fetal outcomes between vaccinated and unvaccinated groups. Conclusion: The overall rate of severe COVID-19 in pregnant women was low. COVID-19 vaccination did not significantly impact maternal outcomes, except for the use of LMWH. Additionally, the study found no significant differences in fetal outcomes and pregnancy complications between vaccinated and unvaccinated individuals.

10 April 2026 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
JLJ. Lin
J. Lin
XWX. Wang
X. Wang
YCY. Chen
Y. Chen
LNL. Nguyen‐Hoang
L. Nguyen‐Hoang
ATA. S. T. Tai
A. S. T. Tai
LPLiona C. Poon
Liona C. Poon
Objective: To evaluate maternal cardiac adaptation during pregnancy by comparing longitudinal hemodynamic profiles between women identified as high risk for preterm pre‐eclampsia (PE) who subsequently developed preterm PE, term PE or remained unaffected, as well as low‐risk women. Methods: This was a prospective longitudinal study of 1078 Chinese women with a singleton pregnancy who were enrolled in a first‐trimester screen‐and‐prevent program for preterm PE at the Prince of Wales Hospital, Hong Kong SAR, China, between January 2020 and June 2024. Participants were classified as high or low risk for preterm PE based on the Fetal Medicine Foundation first‐trimester combined test. Participants were followed up at 12 + 0 to 15 + 6 weeks' gestation, 20 + 0 to 24 + 6 weeks and 30 + 0 to 37 + 6 weeks to measure hemodynamic variables, including heart rate (HR), stroke volume (SV), cardiac output (CO), systemic vascular resistance (SVR) and mean arterial pressure (MAP). Participants were categorized into four groups according to risk status for preterm PE and subsequent development of PE: low risk who did not develop PE (Group 1, n = 407); high risk who did not develop PE (Group 2, n = 598); high risk who developed term PE (Group 3, n = 29); and high risk who developed preterm PE (Group 4, n = 44). Hemodynamic variables were log 10 transformed and analyzed using linear mixed‐effects models, adjusting for maternal characteristics and clinical visits. Estimated marginal means of log 10 ‐transformed values for hemodynamic variables were compared between the groups throughout pregnancy and at each clinical visit. Results: Compared with Group 1, all high‐risk groups exhibited lower SV and CO and higher SVR and MAP throughout pregnancy (all P < 0.05), while HR was significantly elevated in Group 2 ( P < 0.001). Compared with Group 2, Group 4 had lower HR, SV and CO and higher SVR and MAP throughout pregnancy (all P < 0.01). In contrast, Group 3 showed no significant differences in HR, SV, CO and SVR compared with Group 2 (all P > 0.05), although there was an increase in MAP from midgestation onwards ( P < 0.001). Compared with Group 3, Group 4 exhibited lower CO and higher SVR and MAP throughout pregnancy (all P < 0.05). Conclusions: Compared with low‐risk women who do not develop PE, high‐risk women with or without preterm or term PE exhibit distinct cardiac maladaptation profiles from early to late gestation. These findings offer insight into the different pathophysiological mechanisms underlying PE subtypes and should inform risk stratification. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.